Marizomib (NPI-0052, Salinosporamide A)
| Brand Name: | |
| Generic Name: | Marizomib, salinosporamide A |
| Code Name: | NPI-0052 |
| Company: | Nereus Pharmaceuticals |
| FDA Clinical Phase: | 1 |
Description:
Marizomib (NPI-0052, salinosporide A) is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. Marizomib may be used as an alternative treatment to Velcade (bortezomib), the first approved proteasome inhibitor, because it has shown significant activity against multiple myeloma that was previously resistant to Velcade. Marizomib is often administered orally or intravenously as either a single agent or in combination with other anti-cancer agents.
Clinical Trials:
For a list of clinical trials studying marizomib for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official Web site for marizomib: http://www.nereuspharm.com/NPI-0052.shtml
Related Articles:
- NPI-0052 Shows Promise In Relapsed/Refractory Multiple Myeloma (ASH 2009)
- Marizomib May Be Effective In Relapsed / Refractory Multiple Myeloma (ASH 2011)
- ASH 2008 – Carfilzomib, A Novel Drug Related To Velcade, Reduces Peripheral Neuropathy
- Beacon NewsFlashes – June 20, 2011
- ASH 2011 Multiple Myeloma Update – Day Three Morning: New Therapies
